Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Curr Allergy Asthma Rep. 2013 Jun;13(3):322-8. doi: 10.1007/s11882-012-0321-0.
Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.
干眼症（DES）的特征是泪液量和/或质量不足，导致慢性眼表面刺激和炎症。影响高达 30%的成年人，DES 对视觉功能和生活质量有相当大的影响。DES 可能使过敏性眼病复杂化，过敏药物可能使 DES 恶化。DES 的病理生理学涉及泪膜、上皮和上皮下神经丛的渗透、机械和炎症损伤。各种免疫相关的分子靶标一直是研究的焦点，旨在开发治疗 DES 的新治疗药物。本文概述了治疗 DES 的现有、新型和未来药物。
